DM0000: The mark consists of the letters "NMD" in dark grey with a green diamond over the letter "M" followed by the word "PHARMA" in light grey over the wording "NEUROMUSCULAR DISORDERS" in light grey.
B00001: In the statement, in the heading, " International Class 5 " is corrected per the restriction and the fnote dated 11/14/2019.
GS0051: Chemical-pharmaceutical preparations for the treatment of rare and genetic diseases; chemical-pharmaceutical preparations for the treatment of neurodegenerative diseases; chemical-pharmaceutical preparations for the treatment of neuromuscular disorders; chemical-pharmaceutical preparations that strengthen neuromuscular transmission and muscle function in patients with neuromuscular disorders; chemical-pharmaceutical preparations for the treatment of neuromuscular disorders caused by compromised skeletal muscle excitability; diagnostic preparations for medical purposes; reagents for medical purposes [ and for research ] ; preparations for analysis for medical [ and research ] purposes; pharmaceutical and medical preparations for the treatment of rare and genetic diseases; pharmaceutical and medical preparations for the treatment of neurodegenerative diseases; pharmaceutical and medical preparations for the treatment of neuromuscular disorders; pharmaceutical and medical preparations that strengthen neuromuscular transmission and muscle function in patients with neuromuscular disorders; pharmaceutical and medical preparations for acute hospital care, namely, chemical-pharmaceutical preparations for the reversal of neuromuscular blockade, chemical-pharmaceutical preparations for the treatment of intensive care unit acquired muscle weakness, chemical-pharmaceutical preparations for the treatment of neuromuscular disorders caused by infections
CC0000: The color(s) dark grey, light grey, and green is/are claimed as a feature of the mark.
DS0000: "PHARMA" AND "NEUROMUSCULAR DISORDERS"
GS0421: Scientific and technological services and research, namely, research in the field of medicine and the development of pharmaceutical preparations; industrial analysis and research services in the field of development of pharmaceutical preparations, and in the field of identification of drug candidates; drug discovery services; basic research and clinical research, hereunder in the field of medicine and vaccine development; development of medical treatments related to rare and genetic diseases; development of medical treatments related to neurodegenerative diseases; development of medical treatments related to neuromuscular disorders; development of medical treatments that strengthen neuromuscular transmission and muscle function in patients with neuromuscular disorders; development of medical treatments for acute hospital care
Case File Event Statements
8/15/2018 - 7 years ago
2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTEREDType:NWOS
8/9/2018 - 7 years ago
1 - SN ASSIGNED FOR SECT 66A APPL FROM IBType:REPR
8/21/2018 - 7 years ago
3 - APPLICATION FILING RECEIPT MAILEDType:MAFR
9/10/2018 - 7 years ago
4 - ASSIGNED TO EXAMINERType:DOCK
9/17/2018 - 7 years ago
5 - NON-FINAL ACTION WRITTENType:CNRT
9/18/2018 - 7 years ago
6 - NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEWType:RFCR
9/22/2018 - 7 years ago
7 - REFUSAL PROCESSED BY MPUType:RFRR
3/4/2019 - 6 years ago
11 - CORRESPONDENCE RECEIVED IN LAW OFFICEType:CRFA
9/22/2018 - 7 years ago
8 - NON-FINAL ACTION MAILED - REFUSAL SENT TO IBType:RFCS
10/13/2018 - 7 years ago
9 - REFUSAL PROCESSED BY IBType:RFNT
3/4/2019 - 6 years ago
10 - TEAS RESPONSE TO OFFICE ACTION RECEIVEDType:TROA
3/5/2019 - 6 years ago
12 - TEAS/EMAIL CORRESPONDENCE ENTEREDType:TEME
3/18/2019 - 6 years ago
13 - EXAMINERS AMENDMENT -WRITTENType:CNEA
3/18/2019 - 6 years ago
14 - EXAMINERS AMENDMENT E-MAILEDType:GNEA
3/18/2019 - 6 years ago
15 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILEDType:GNEN
3/18/2019 - 6 years ago
16 - EXAMINER'S AMENDMENT ENTEREDType:XAEC
3/18/2019 - 6 years ago
17 - APPROVED FOR PUB - PRINCIPAL REGISTERType:CNSA
4/17/2019 - 6 years ago
18 - NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IBType:OP2R
4/17/2019 - 6 years ago
19 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILEDType:NONP
4/17/2019 - 6 years ago
20 - NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IBType:OPNS
4/30/2019 - 6 years ago
21 - TEAS CHANGE OF CORRESPONDENCE RECEIVEDType:TCCA
5/3/2019 - 6 years ago
22 - NOTIFICATION PROCESSED BY IBType:GPNX
5/7/2019 - 6 years ago
23 - PUBLISHED FOR OPPOSITIONType:PUBO
5/7/2019 - 6 years ago
24 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILEDType:NPUB
7/23/2019 - 6 years ago
25 - REGISTERED-PRINCIPAL REGISTERType:R.PR
8/23/2019 - 6 years ago
26 - LIMITATION OF GOODS RECEIVED FROM IBType:LIMG
10/23/2019 - 6 years ago
27 - FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IBType:FICR
11/14/2019 - 5 years ago
28 - FINAL DISPOSITION PROCESSEDType:FIMP
11/14/2019 - 5 years ago
29 - LIMITATION FROM THE IB EXAMINED AND ENTEREDType:LIME
11/14/2019 - 5 years ago
30 - FINAL DISPOSITION NOTICE SENT TO IBType:FICS
11/21/2019 - 5 years ago
31 - CASE ASSIGNED TO POST REGISTRATION PARALEGALType:APRE
11/21/2019 - 5 years ago
32 - CORRECTION UNDER SECTION 7 - PROCESSEDType:COC.
7/26/2020 - 5 years ago
34 - PARTIAL INVALIDATION OF REG EXT PROTECTION CREATEDType:INPR
12/6/2019 - 5 years ago
33 - FINAL DECISION TRANSACTION PROCESSED BY IBType:FINO
9/9/2023 - 2 years ago
36 - CHANGE OF NAME/ADDRESS REC'D FROM IBType:ADCH
7/23/2024 - a year ago
37 - COURTESY REMINDER - SEC. 71 (6-YR) E-MAILEDType:REM3
9/3/2020 - 5 years ago
35 - INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICEType:INNA
Trademark
79238525
